COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature

被引：17
作者：
Alshanqeeti, Shatha [1 ,2 ]
Bhargava, Ashish [1 ]
机构：
[1] Ascension St John Hosp, Internal Med, Detroit, MI 48236 USA
[2] King Saud Univ, Infect Dis, Riyadh, Saudi Arabia
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2022年 / 14卷 / 06期
关键词：
covid-19; protease inhibitor; paxlovid; nirmatrelvir; ritonavir;
D O I：
10.7759/cureus.26239
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to prevent progression to severe disease. Relapse of symptoms following a period of improvement after treatment with Paxlovid has been described recently. Data are limited, but the disease course in available case reports is usually mild and requires no additional antiviral treatment. We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid.
引用
收藏
页数：6
相关论文
共 9 条
  • [1] [Anonymous], 2022, HAN ARCH 00467 COVID
  • [2] COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021
    Birhane, Meseret
    Bressler, Sara
    Chang, Gregory
    Clark, Thomas
    Dorough, Layne
    Fischer, Marc
    Watkins, Louise Francois
    Goldstein, Jason M.
    Kugeler, Kiersten
    Langley, Gayle
    Lecy, Kristin
    Martin, Stacey
    Medalla, Felicita
    Mitruka, Kiren
    Nolen, Leisha
    Sadigh, Katrin
    Spratling, Robin
    Thompson, Gail
    Trujillo, Alma
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (21): : 792 - 793
  • [3] CDC, 2020, UND MED COND ASS HIG
  • [4] Charness M, 2022, PREPRINT, DOI DOI 10.21203/RS.3.RS-1588371/V1
  • [5] Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
    Hammond, Jennifer
    Leister-Tebbe, Heidi
    Gardner, Annie
    Abreu, Paula
    Bao, Weihang
    Wisemandle, Wayne
    Baniecki, MaryLynn
    Hendrick, Victoria M.
    Damle, Bharat
    Simon-Campos, Abraham
    Pypstra, Rienk
    Rusnak, James M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) : 1397 - 1408
  • [6] ORIGINAL RESEARCH Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021
    Kompaniyets, Lyudmyla
    Pennington, Audrey F.
    Goodman, Alyson B.
    Rosenblum, Hannah G.
    Belay, Brook
    Ko, Jean Y.
    Chevinsky, Jennifer R.
    Schieber, Lyna Z.
    Summers, April D.
    Lavery, Amy M.
    Preston, Leigh Ellyn
    Danielson, Melissa L.
    Cui, Zhaohui
    Namulanda, Gonza
    Yusuf, Hussain
    Mac Kenzie, William R.
    Wong, Karen K.
    Baggs, James
    Boehmer, Tegan K.
    Gundlapalli, Adi V.
    [J]. PREVENTING CHRONIC DISEASE, 2021, 18
  • [7] Antiviral Drug Discovery for the Treatment of COVID-19 Infections
    Ng, Teresa, I
    Correia, Ivan
    Seagal, Jane
    DeGoey, David A.
    Schrimpf, Michael R.
    Hardee, David J.
    Noey, Elizabeth L.
    Kati, Warren M.
    [J]. VIRUSES-BASEL, 2022, 14 (05):
  • [8] nih, 2022, RIT BOOST NIRM PAXL
  • [9] U.S. Food & Drug Administration, 2021, NEWS RELEASE
1